State of the Art Urinary Pathogen Detection

The Absolute Genomics Urinary InSITE pathogen panel is based on cutting-edge RT-PCR and OpenArray technology. This multiplex approach allows Absolute Genomics to run more samples on a single OpenArray plate. From extraction to result generation, this process has a rapid turnaround time of hours rather than . A comparison study demonstrated that the Absolute Genomics Urinary InSITE pathogen panel is 33% more accurate than the traditional culturing methods. With this high-throughput technique, our sample capacity has significantly increased. The Absolute Genomics Urinary InSITE panel has a diverse target list including both bacterial and fungal pathogens. Along with pathogen detection, we provide a powerful antibiotic stewardship report that helps physicians make key decisions for selecting a treatment regimen.

Clinical Need :

U.S. epidemiological statistics show that UTIs are the most common hospital and community acquired infections
According to recent estimates, there ~8 million UTIs in the U.S. annually
Hospital estimates show ~1 million urinary-related emergency department cases
Total losses due to hospitalization and treatment amount to ~$3 billion in the U.S. every year
UTIs are often associated with catheters, urine tubes, urinary tract stones, and other obstructions
Gram negative bacteria are most prevalent UTI bacterial pathogens
Individuals with a history of diabetes, drug resistance, or immunosuppression can harbor fungal agents as UTI pathogens
~50% of all women infected with a UTI pathogen become infected again within a year

~50% of all women experience at least 1 UTI by age 35

~8 million UTIs in the U.S. annually

~50% of all women experience at least 1 UTI by age 35

ABx Advantage

The Absolute Genomics ABx Advantage gene panel is designed to detect major classes of antibiotic resistance. This panel can identify the presence of specific resistance genes that are involved in drug inhibition. The Absolute Genomics ABx Advantage gene panel has 11 antibiotic resistance genes belonging to amino glycosidea β-lactama fluoroquinolonea macrolidea tetracyclinea vancomycina and multi-drug resistance classifications. The data is used for providing antibiotic resistance stewardship via Arkstone Medical Solutions. The OneChoice report powered by Arkstone Medical Solutions for the ABx Advantage gene panel converts PCR data into simple interpretations for physicians to help them make better treatment decisions. This technology is a combination of softwarea artificial intelligencea and human expertise.

The antimicrobial report contains a unique ArkScore to help prescribers make informed decisions.
The antimicrobial decision engine combines machine-learning artificial intelligence with decades of deep infectious disease expertise to guide physicians to a singular treatment regimen that targets the most relevant infectiona with the lowest risk to the patient.
ArkScore describes the level of antimicrobial resistance expressed in organisms.
ArkScore provides the most effective treatment with the least risk of adverse events resulting in the reduction of unnecessary use of broad-spectrum antibiotics